Genelex Information References
All of the information contained on Genelex.com has been sourced from the following links or publications. If you have any questions about the information on our website, please email us at info@genelex.com.
Last updated: November 9, 2018
| Citation # | Page | Citation | Link |
|---|---|---|---|
| 1 | Patients | 1. Van Driest, SL, et. al., Clin Pharmacol Ther. 2014; 95(4): 423–431. 2. Yuan, J. et. al., Jmol Diag. 2016; 18(3): 438-445 | https://www.ncbi.nlm.nih.gov/pubmed/24253661 |
| 2 | Patients | https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm | https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm |
| 3 | Conditions | Center for Drug Evaluation and Research. (n.d.). Science & Research (Drugs) - Table of Pharmacogenomic Biomarkers in Drug Labeling. Retrieved from http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm | http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm |
| 4 | Cancer | Flockhart, D. A. (2007). Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine , 2010 . | https://drug-interactions.medicine.iu.edu/main-table.aspx |
| 5 | Cancer | Brian Thomas Hocum, John Raymond White, Jarrod W. Heck, Ranjit K. Thirumaran, Nicolas Moyer, Richard Newman and Kristine Ashcraft American Journal of Health-System Pharmacy January 2016, 73 (2) 61-67; DOI: https://doi.org/10.2146/ajhp150273 | https://www.ncbi.nlm.nih.gov/pubmed/26721535 |
| 6 | Cancer | (n.d.). Retrieved from https://www.pharmgkb.org/labels | https://www.pharmgkb.org/labels |
| 7 | Depression | Al-Harbi, K. S. (2012). Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Preference and Adherence, 6, 369–388. http://doi.org/10.2147/PPA.S29716 | https://www.ncbi.nlm.nih.gov/pubmed/22654508 |
| 8 | Depression | CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19. (n.d.). Retrieved from https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/ | https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/ |
| 5 | Depression | Brian Thomas Hocum, John Raymond White, Jarrod W. Heck, Ranjit K. Thirumaran, Nicolas Moyer, Richard Newman and Kristine Ashcraft American Journal of Health-System Pharmacy January 2016, 73 (2) 61-67; DOI: https://doi.org/10.2146/ajhp150273 | https://www.ncbi.nlm.nih.gov/pubmed/26721535 |
| 9 | Depression | (n.d.). Retrieved from https://www.pharmgkb.org/labels | https://www.pharmgkb.org/labels |
| 10 | Diabetes | CDC Newsroom. (n.d.). Retrieved from https://www.cdc.gov/media/releases/2014/p0610-diabetes-report.html | https://www.cdc.gov/media/releases/2014/p0610-diabetes-report.html |
| 11 | Diabetes | Horn, J., PharmD, & Hansten, P., PharmD. (2004). Oral Hypoglycemic Agents: The Risk of Hypoglycemia APRIL 01, 2004 John R. Horn, PharmD, FCCP, and Philip D. Hansten, PharmD. Pharmacy Times, 2004(04). Retrieved September 26, 2018. | https://www.pharmacytimes.com/publications/issue/2004/2004-04/2004-04-7837 |
| 12 | Epilepsy | https://www.ncbi.nlm.nih.gov/pubmed/27713373 | https://www.ncbi.nlm.nih.gov/pubmed/27713373 |
| 13 | Heart Disease | Johnson, J. A., & Cavallari, L. H. (2013). Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine. Pharmacological Reviews, 65(3), 987–1009. http://doi.org/10.1124/pr.112.007252 | http://pharmrev.aspetjournals.org/content/65/3/987 |
| 14 | Heart Disease | Cavallari, L. H., & Weitzel, K. (2015). Pharmacogenomics in cardiology – genetics and drug response: 10 years of progress. Future Cardiology, 11(3), 281–286. http://doi.org/10.2217/fca.15.20 | http://doi.org/10.2217/fca.15.20 |
| 15 | Heart Disease | (n.d.). Retrieved from https://www.pharmgkb.org/labels | https://www.pharmgkb.org/labels |
| 16 | HIV | Kumar S, Rao P, Earla R, Kumar A. Drug–drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert opinion on drug metabolism & toxicology. 2015;11(3):343-355. doi:10.1517/17425255.2015.996546. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428551/ |
| 17 | Chronic Pain | Schug, S., & Ting, S. (2016). The pharmacogenomics of pain management: Prospects for personalized medicine. Journal of Pain Research, 49. doi:10.2147/jpr.s55595 | https://www.ncbi.nlm.nih.gov/pubmed/26929662 |
| 18 | Chronic Pain | Agarwal, D., Udoji, M. A., & Trescot, A. (2017). Genetic Testing for Opioid Pain Management: A Primer. Pain and Therapy, 6(1), 93–105. http://doi.org/10.1007/s40122-017-0069-2 | http://doi.org/10.1007/s40122-017-0069-2 |
| 18 | Ulcers/Acid Refulx | Klotz U, Schwab M, Treiber G. CYP2C19Polymorphism and Proton Pump Inhibitors. Basic & Clinical Pharmacology & Toxicology. 2004;95(1):2–8. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548122/ |
| 19 | Fluorouracil | Dean L. Fluorouracil Therapy and DPYD Genotype. 2016 Nov 3. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395610/ | https://www.ncbi.nlm.nih.gov/books/NBK395610/ |
| 20 | Plavix | Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., . . . Becquemont, L. (2009). Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New England Journal of Medicine,360(4), 363-375. doi:10.1056/nejmoa0808227 | https://www.nejm.org/doi/full/10.1056/NEJMoa0808227 |
| 21 | Tamoxifen | Dean L. Tamoxifen Therapy and CYP2D6 Genotype. 2014 Oct 7 [Updated 2016 May 3]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK247013/ | |
| 22 | Strattera | https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021411s035lbl.pdf | |
| 23 | Strattera | Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact, Drug Metabolism Reviews, 41:2, 89-295, DOI: 10.1080/03602530902843483 | https://www.tandfonline.com/action/showCitFormats?doi=10.1080%2F03602530902843483 |
| 24 | Warfarin | Johnson, J. A., & Cavallari, L. H. (2015). Warfarin Pharmacogenetics. Trends in Cardiovascular Medicine, 25(1), 33–41. http://doi.org/10.1016/j.tcm.2014.09.001 | https://www.ncbi.nlm.nih.gov/pubmed/25282448 |
| 27 | Warfarin | Dean L. Warfarin Therapy and VKORC1 and CYP Genotype. 2012 Mar 8 [Updated 2018 Jun 11]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK84174/ | https://www.ncbi.nlm.nih.gov/books/NBK84174/ |
| 28 | Warfarin | Johnson, J., Caudle, K., Gong, L., Whirl-Carrillo, M., Stein, C., Scott, S., . . . Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology & Therapeutics, 102 (3), 397-404. doi:10.1002/cpt.668 | https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/ |
| 29 | CYP2C9 | Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther . 2013;17(3):165-84. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663206/ |
| 30 | CYP2C9 | Wise ES, Gadomski SP, McMaster WG, et al. The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty. J Orthop . 2015;12(Suppl 2):S145-51. Published 2015 Nov 28. doi:10.1016/j.jor.2015.10.023 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796661/ |
| 31 | CYP2C19 | Kaneko, A., Lum, J. K., Yaviong, L., Takahashi, N., Ishizaki, T., Bertilsson, L., et al. (1999). High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 9, 581–590. | https://www.ncbi.nlm.nih.gov/pubmed/10591538 |
| 33 | CYP2D6 | Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med . 2014;21(8):879-85. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150819/ |
| 34 | CYP3A4 | PharmGKB summary: very important pharmacogene information for CYP3A5.Pharmacogenetics and genomics. 2012. Lamba Jatinder, Hebert Joan M, Schuetz Erin G, Klein Teri E, and Altman Russ B. 22407409 | https://www.pharmgkb.org/vip/PA166169915 |
| 35 | CYP3A5 | PharmGKB summary: very important pharmacogene information for CYP3A5.Pharmacogenetics and genomics. 2012. Lamba Jatinder, Hebert Joan M, Schuetz Erin G, Klein Teri E, and Altman Russ B. 22407409 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738061/ |
| 37 | ADRA2A | Huang, H.-C., Wu, L. S.-H., Yu, S.-C., Wu, B.-J., Lua, A. C., Lee, S.-M., & Liu, C.-Z. (2018). The Alpha-2A Adrenergic Receptor Gene -1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder. Psychiatry Investigation, 15(3), 306–312. http://doi.org/10.30773/pi.2017.07.24 | http://doi.org/10.30773/pi.2017.07.24 |
| 39 | CYP1A2 | Kroon, L. A. (2007). Drug interactions with smoking. American Journal of Health-System Pharmacy,64(18), 1917-1921. doi:10.2146/ajhp060414 | http://www.ajhp.org/content/64/18/1917?sso-checked=true |
| 38 | CYP1A2 | Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R. B. (2012). PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenetics and Genomics, 22(1), 73–77. http://doi.org/10.1097/FPC.0b013e32834c6efd | https://www.ncbi.nlm.nih.gov/pubmed/21989077 |
| 40 | CYP2B6 | Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet . 2013;4:24. Published 2013 Mar 5. doi:10.3389/fgene.2013.00024 | https://www.ncbi.nlm.nih.gov/pubmed/23467454 |
| 42 | CYP4F2 and VKORC1 | Dean L. Warfarin Therapy and VKORC1 and CYP Genotype. 2012 Mar 8 [Updated 2018 Jun 11]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK84174/ | https://www.ncbi.nlm.nih.gov/pubmed/28520347 |
| 43 | CYP4F2 and VKORC1 | Shendre, A., Brown, T. M., Liu, N., Hill, C. E., Beasley, T. M., Nickerson, D. A., & Limdi, N. A. (2016). Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy, 36(3), 263–272. http://doi.org/10.1002/phar.1717 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803610/ |
| 45 | COMT | 2. Lin, C., Fan, J., Lin, H., Chang, C., & Wu, Y. (2018). Catechol-O-methyltransferase ( COMT ) genetic variants are associated with cognitive decline in patients with Parkinsons disease. Parkinsonism & Related Disorders, 50, 48-53. doi:10.1016/j.parkreldis.2018.02.015 | https://www.ncbi.nlm.nih.gov/pubmed/29439855 |
| 46 | DPYD | Del Re M, Di Paolo A, van Schaik RH, et al. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. EPMA J . 2010;1(3):495-502. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405332/ |
| 47 | Factor II Factor V Leiden | Laberge, A.-M., Psaty, B. M., Hindorff, L. A., & Burke, W. (2009). Use of Factor V Leiden genetic testing in practice and impact on management. Genetics in Medicine : Official Journal of the American College of Medical Genetics, 11(10), 750–756. http://doi.org/10.1097/GIM.0b013e3181b3a697 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132195/ |
| 49 | Grik4 | Paddock, Silvia & Laje, Gonzalo & Charney, Dennis & Rush, Augustus & F Wilson, Alexander & J M Sorant, Alexa & Lipsky, Robert & R Wisniewski, Stephen & Manji, Husseini & Mcmahon, Francis. (2007). Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort. The American journal of psychiatry. 164. 1181-8. 10.1176/appi.ajp.2007.06111790. | http://europepmc.org/abstract/med/17671280 |
| 50 | HLA-A/B | Dean L. Abacavir Therapy and HLA-B*57:01 Genotype. 2015 Sep 1 [Updated 2018 Apr 18]. In: Pratt V, McLeod H, Rubinstein W, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK315783/ | https://www.ncbi.nlm.nih.gov/books/NBK315783/ |
| 51 | HLA-A/B | Cheng, C.-Y., Su, S.-C., Chen, C.-H., Chen, W.-L., Deng, S.-T., & Chung, W.-H. (2014). HLA Associations and Clinical Implications in T-Cell Mediated Drug Hypersensitivity Reactions: An Updated Review. Journal of Immunology Research, 2014, 565320. http://doi.org/10.1155/2014/565320 | https://www.ncbi.nlm.nih.gov/pubmed/24901010 |
| 52 | HTR2A | Dong ZQ, Li XR, He L, He G, Yu T, Sun XL. 5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients. Neuropsychiatr Dis Treat . 2016;12:1623-9. Published 2016 Jul 4. doi:10.2147/NDT.S93562 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938133/ |
| 53 | HTR2A | Stevenson JM, Bishop JR (2013) Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Genotypes. Clin Pharmacol Biopharm 2:109. doi:10.4172/2167-065X.1000109 | https://www.omicsonline.org/open-access/antidepressant-tolerability-and-potential-clinical-implications-of-serotonin-2a-genotypes-2167-065X.1000109.php?aid=16184 |
| 54 | HTR2C | Drago A, Serretti A. 2009. Focus on HTR2C: A Possible Suggestion for Genetic Studies of Complex Disorders. Am J Med Genet Part B 150B:601–637. | https://onlinelibrary.wiley.com/doi/10.1002/ajmg.b.30864 |
| 55 | HTR2C | Wallace, T. J., Zai, C. C., Brandl, E. J., & Müller, D. J. (2011). Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmacogenomics and personalized medicine , 4 , 83-93. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513221/ |
| 56 | INFL3 | Nakamoto, S., Imazeki, F., Kanda, T., Wu, S., Nakamura, M., Yasui, S., Tawada, A., Mikata, R., Chiba, T., Arai, M., Yokosuka, O., … Shirasawa, H. (2017). Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. International journal of medical sciences , 14 (11), 1088-1093. doi:10.7150/ijms.20171 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666539/ |
| 58 | NAT2 | PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.Pharmacogenetics and genomics. 2014. McDonagh Ellen M, Boukouvala Sotiria, Aklillu Eleni, Hein David W, Altman Russ B, and Klein Teri E. 24892773 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109976/ |
| 60 | OPRM1 | Mura, E., Govoni, S., Racchi, M., Carossa, V., Ranzani, G. N., Allegri, M., & van Schaik, R. H. (2013). Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?. Journal of pain research , 6 , 331-53. doi:10.2147/JPR.S42040 | https://www.dovepress.com/consequences-of-the-118agtg-polymorphism-in-the-oprm1-gene-translation-peer-reviewed-article-JPR |
| 61 | SLCO1B1 | Birmingham, B.K., Bujac, S.R., Elsby, R. et al. Eur J Clin Pharmacol (2015) 71: 341. https://doi.org/10.1007/s00228-014-1801-z | https://www.ncbi.nlm.nih.gov/pubmed/25673568 |
| 62 | SLCO1B1 | Oshiro, C., Mangravite, L., Klein, T., & Altman, R. (2010). PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenetics and Genomics, 20(3), 211–216. http://doi.org/10.1097/FPC.0b013e328333b99c | https://insights.ovid.com/crossref?an=01213011-201003000-00007 |
| 63 | SLCO1B1 | Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., … Niemi, M. (2014). The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology and Therapeutics, 96(4), 423–428. http://doi.org/10.1038/clpt.2014.125 | https://www.ncbi.nlm.nih.gov/pubmed/24918167 |
| 64 | TMPT | Wang, L., Pelleymounter, L., Weinshilboum, R., Johnson, J. A., Hebert, J. M., Altman, R. B., & Klein, T. E. (2010). Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenetics and genomics , 20 (6), 401-5. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086840/ |
| 65 | UTG1A1 | PharmGKB summary: very important pharmacogene information for UGT1A1.Pharmacogenetics and genomics. 2014. Barbarino Julia M, Haidar Cyrine E, Klein Teri E, and Altman Russ B. 24492252 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091838/ |
| 67 | Providers | D. Brixner, E. Biltaji, A. Bress, S. Unni, X. Ye, T. Mamiya, K. Ashcraft & J. Biskupiak (2016) The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy, Journal of Medical Economics, 19:3, 213-228,DOI: 10.3111/13696998.2015.1110160 | https://www.ncbi.nlm.nih.gov/pubmed/26478982 |
| 68 | Providers | Elliott, L. S., Henderson, J. C., Neradilek, M. B., Moyer, N. A., Ashcraft, K. C., & Thirumaran, R. K. (2017). Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PloS one , 12 (2), e0170905. doi:10.1371/journal.pone.0170905 | https://www.ncbi.nlm.nih.gov/pubmed/28151991 |
| 69 | Home | Klein, E., & Bourdette, D. (2013). Postmarketing adverse drug reactions: A duty to report?. Neurology. Clinical practice , 3 (4), 288-294. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787113/ |
| 70 | Home | Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK (2017) Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS ONE 12(2): e0170905. doi:10.1371/journal.pone.0170905 | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170905 |